ストックスクリーナーアプリを入手
90.31
0.83%
0.74
Alcon Inc (ALC) 最新ニュース
Alcon Hit With Suit Over Allegedly Contaminated Eye Drops - Law360
Wall Street's Insights Into Key Metrics Ahead of Alcon (ALC) Q4 Earnings - MSN
Alcon launches Voyager laser trabeculoplasty platform in US - Optics.org
Alcon Releases Voyager DSLT for Glaucoma & Ocular Hypertension in U.S. - MPO-mag
Alcon to Roll Out New Glaucoma, Ocular Hypertension Laser Therapy in US -February 19, 2025 at 09:17 am EST - Marketscreener.com
Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension - Business Wire
Alcon Inc.'s (VTX:ALC) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat? - Simply Wall St
Growth Report 2: Alcon Mechanical Plans Tech Investments - businessjournaldaily.com
Judge Finds No Infringement In Alcon's Eye Drop Patent Suit - Law360
Alcon Fights for Veto Rights in Aurion's Planned Public Offering - Bloomberg Law
Alcon Loses Patent Ruling on Padagis Copy of Simbrinza Eye Drops - Bloomberg Law
Alcon: T. Rowe Price above 3% of voting rights -February 10, 2025 at 10:40 am EST - Marketscreener.com
Tesla, Musk, Warner Bros. Ask To Toss 'Blade Runner' AI Suit - Law360
Alcon: An Eyecare Leader With Strong Profit Margins, But Overheated Valuation - Seeking Alpha
Alcon Laboratories is considering a major $100M expansion of its Fort Worth campus - AOL
Alcon Loses Bid to Veto Aurion IPO, Can Still Oppose Listing (1) - Bloomberg Law
Intraocular Lens Market Forecast and Company Analysis Report 2025-2033 Featuring Alcon, Bausch Health, Hoya, Johnson & Johnson, STAAR Surgical Co, Carl Zeiss Meditec, and Novartis - GlobeNewswire
Alcon stock price target cut to $106 by Needham, maintains Buy - MSN
Alcon Breaks Above 200-Day Moving AverageBullish for ALC - Nasdaq
Artificial Tears Market Overall Study Report 2025-2032 | - openPR
Alcon stock price target cut to $105 by KeyBanc - MSN
Apple To $253? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Do Options Traders Know Something About Alcon (ALC) Stock We Don't? - Yahoo Finance
First Week of March 21st Options Trading For Alcon (ALC) - Nasdaq
Alcon Inc (ALC) Shares Up 3.7% on Jan 21 - GuruFocus.com
Modernizing a Legacy Application on AWS Serverless with Alcon - AWS Blog
Modernizing a Legacy Application on AWS Serverless with Alcon | Case Study | AWS - AWS Blog
Alcon to Seek M&A -January 14, 2025 at 07:30 pm EST - Marketscreener.com
Should Weakness in Alcon Inc.'s (VTX:ALC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - Yahoo Finance
Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge - GlobeNewswire Inc.
Redburn raises Alcon stock rating to Buy By Investing.com - Investing.com Nigeria
Redburn raises Alcon stock rating to Buy - Investing.com
Dry Eye Disease Market Is Booming Worldwide 2025-2032 | Novartis - openPR
Contact Lens Market Deep Research Report with Forecast by 2031 | Bausch & Lomb Incorporated, Alcon Vision LLC - EIN News
Alcon Inc. (VTX:ALC) is favoured by institutional owners who hold 63% of the company - Simply Wall St
Seeing Brilliance in APAC: Alcon’s Vision Care Innovations and Eye Health Mission - BSA bureau
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference - Marketscreener.com
Alcon Laboratories issues recall for Systane eye drops due to fungal contamination - Top Class Actions
News Release – DOH Issues Recall Alert For Alcon Laboratories Systane Brand Lubricant Eye Drops Due to Fungal - EIN News
DOH issues recall alert for Alcon Laboratories Systane Brand Lubricant Eye Drops - Maui Now
Alcon Labs recalling eye drops - Valley News
Alcon Laboratories Recalls Systane Eye Drops Nationwide Over Fungal Contamination Risk - Black Enterprise
Alcon's (VTX:ALC) investors will be pleased with their respectable 41% return over the last five years - Simply Wall St
0.47%
1.14%
大文字化:
|
ボリューム (24 時間):